DTB Navarre

Bulletin to provide independent information on pharmacotherapy, improve patient care and contribute to the sustainability of the public health system

[JAMA @JAMA_current]

📊 Research Summary: Adjuvant #nivolumab did not significantly improve disease-free or overall survival compared with observation after #surgery and standard therapy in resected non-small cell lung #cancer (NSCLC), regardless of PD-L1 expression.

#ASCO26 @ASCO

https://t.co/EVSDdb9tlg

[DTB Navarre @DTB_Navarre]

📢📢 New drug assessment report 📢📢
Therapeutic personalisation II: pharmacogenetics
@salud_na
https://t.co/GM41050uvU
@jbelliz

[DTB Navarre @DTB_Navarre]

📢 📢New drug assessment report- Vibegron for overactive bladder: One less urination every 2 days 📢📢

https://t.co/ZoG4LMskjU

@salud_na

[DTB Navarre @DTB_Navarre]

Ataluren for Duchenne: how politics and social pressure undermined evidence-based decisions https://t.co/74EUD7LMrw

[DTB Navarre @DTB_Navarre]

📢📢 Therapeutic personalisation I: practical aspects of pharmacokinetic monitoring 📢📢
https://t.co/Oj083nt2ev
@mariacalvoar @salud_na

[DTB Navarre @DTB_Navarre]

📢📢Beyond statins: evidence for other lipid-lowering drugs in patients with atherosclerotic cardiovascular disease
https://t.co/rs3oQpvR32
@BITNavarra @salud_na

[DTB Navarre @DTB_Navarre]

📢📢 New drug assessment report 📢📢 Tirzepatide. Unknowns regarding its efficacy in morbidity and mortality
@salud_na
https://t.co/ajGhX5HuE0

[DTB Navarre @DTB_Navarre]

📢📢Surrogate outcomes and fast-track drug approval. Towards reversing the burden of proof?
https://t.co/PDSdKWwlXv
@BITNavarra @salud_na

[DTB Navarre @DTB_Navarre]

📢📢Glucagon-like peptide 1 receptor agonists (GLP1a) and the problem of obesity
https://t.co/wXNXMJTw7E

@BITNavarra @salud_na

[DTB Navarre @DTB_Navarre]

(Cochrane Library) Blood pressure targets for hypertension in people with chronic renal disease

https://t.co/wcD07pFx5q

[DTB Navarre @DTB_Navarre]

📢New drug assessment report:
FINERENONE IN CHRONIC KIDNEY DISEASE ASSOCIATED WITH TYPE 2 DIABETES
https://t.co/3OjsRNWLAE

[DTB Navarre @DTB_Navarre]

📢📢New drug assessment report 📢📢 Dapagliflozin for heart failure with mildly reduced or preserved ejection fraction
https://t.co/qT6nBvth1F

[DTB Navarre @DTB_Navarre]

📢📢New drug assessment report📢📢 Icosapent Ethil (Omega-3) for hypertriglyceridemia
https://t.co/EtHLgArANh

[DTB Navarre @DTB_Navarre]

📢📢New drug assessment report📢📢
Use of fluid therapy in clinical practice
https://t.co/VDijRyyw99
@BITNavarra

[DTB Navarre @DTB_Navarre]

Long-term effectiveness and safety of tolvaptan in autosomal dominant ... https://t.co/51DwmLYKqH

[DTB Navarre @DTB_Navarre]

📢📢New drug assessment report📢📢 Bempedoic Acid and Bempedoic Acid/Ezetimibe: a mystery for the treatment of hypercholesterolaemia
https://t.co/4677tucY2H

[DTB Navarre @DTB_Navarre]

Spanish version: https://t.co/TJGfaimc9J

[DTB Navarre @DTB_Navarre]

📢📢(dtbn) Safe drug use in patients with cirrhosis
https://t.co/hwDXgySySc

[DTB Navarre @DTB_Navarre]

(dtbn) Long-acting injectable antipsychotics in schizophrenia 💉💉
https://t.co/Tw5Nmq6UHH